Mylan made an unsolicited $28.9 billion offer to buy the Irish drugmaker last week, but Perrigo’s board of directors unanimously rejected the proposal, saying that the merger substantially undervalues the company and its future growth prospects.
Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first...
Shares of Aerie Pharmaceuticals lost two-thirds of their value in after-market trading after the...
The product is indicated for the treatment of chronic hepatitis C, a blood-borne infectious disease that affects more than 100 million people in the developing world, including approximately 12 million people in India.
The Roche Group posted strong sales growth in the first three months in both divisions, with demand for oncology and immunology medicines driving growth in pharmaceuticals, and immunodiagnostics products driving growth in diagnostics.
A startup company that’s found a unique niche in the exploding cannabis industry, Potbotics uses robotic technology to bring medical marijuana use into a new era of high-tech pharma.
CBRE Group, Inc. announced today that they have been hired to sell Eli Lilly’s biomanufacturing plant in Vacaville, California.
ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has been awarded a 1.5 million Euro contract by one of China’s biggest pharmaceutical companies.
The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as Sun Pharma.
Mylan Executive Chairman Robert J. Coury commented, "We note that there has been some media speculation with regard to a potential bid for Mylan by Teva and that this rumor has been circulating for some time."
Applied Genetic Technologies Corporation and 4D Molecular Therapeutics, leaders in next-generation adeno-associated virus gene therapy vector discovery and product development, today announced a collaboration and license agreement to discover and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need.
A company with deep roots at the University of Wisconsin-Madison wants to make blood sampling less painful and more convenient.
Sartorius Stedim Biotech (SSB), an international supplier for the biopharmaceutical industries, today acquired the Scottish company BioOutsource Ltd.
A group of top doctors has demanded Columbia University remove Dr. Oz, citing his "egregious lack of integrity" for promoting what they call "quack treatments."
Medytox currently owns and operates several healthcare companies, including clinical testing laboratories, an electronic medical records provider, a laboratory information systems company and a medical billing company. CollabRx is a leading informatics company focused on the interpretation of complex molecular and genetic tests in cancer.
Sagent Pharmaceuticals, Inc., a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that its current EVP and Chief Legal Officer Michael Logerfo has been appointed President.
Medac Pharma, Inc., a privately-held pharmaceutical company, today announced that it and its parent company, medac GmbH, have settled all litigation and patent office proceedings with Antares Pharma, Inc.
OriGen Biomedical initiated a nationwide recall for one lot of Reinforced Dual Lumen ECMO catheters.
Catalent Pharma Solutions announced the opening of a large scale expansion at its Winchester, KY, manufacturing facility.
Innocrin Pharmaceuticals is developing small-molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers.
Too-thin models, too much drinking, sexy cigarette packs: France's parliament is cracking down on all of these in a sweeping bill designed to improve public health and trim public health costs.
The Senate gave final approval late Tuesday to the $214 billion bipartisan measure, which permanently recasts how Medicare reimburses doctors for treating over 50 million elderly people.
A 2011 law overhauling the German pharmaceutical industry will be the biggest impediment to growth in the sector over the next several years, according to a new report.
On March 30, the Pharma & Biopharma Outsourcing Association (PBOA) held its first Regulatory/Legislative Workshop.
The global treatment market for Duchenne Muscular Dystrophy (DMD) will expand in value at a staggering Compound Annual Growth Rate (CAGR) of 160.5%, from approximately $8.2 million in 2014 to $990 million by 2019, says research and consulting firm GlobalData.
$2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016.
GE Healthcare Life Sciences and Rentschler Biotechnologie GmbH announced the expansion of Rentschler’s biopharmaceutical manufacturing capabilities.
Ventana, a member of the Roche Group, announced it has entered into a master collaboration agreement with Astellas Pharma Inc.
- Page 1